Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1984 2
1985 1
1992 1
1993 1
1997 1
2001 2
2005 1
2006 5
2007 4
2008 1
2009 1
2011 1
2012 2
2013 2
2014 3
2015 3
2016 2
2017 4
2018 2
2019 3
2020 4
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
AlShimemeri S, Fox SH, Visanji NP. AlShimemeri S, et al. Expert Opin Emerg Drugs. 2020 Jun;25(2):131-144. doi: 10.1080/14728214.2020.1763954. Epub 2020 May 22. Expert Opin Emerg Drugs. 2020. PMID: 32366130 Review.
INTRODUCTION: Prolonged treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of uncontrolled movements (L-DOPA-induced dyskinesias (LID)) in Parkinson's disease (PD). There is currently only a single approved drug for the treatment …
INTRODUCTION: Prolonged treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of uncontrolled movements (L-DO …
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Sebastianutto I, Cenci MA. Sebastianutto I, et al. Curr Opin Pharmacol. 2018 Feb;38:81-89. doi: 10.1016/j.coph.2018.03.003. Epub 2018 Apr 3. Curr Opin Pharmacol. 2018. PMID: 29625424 Review.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes comp …
Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA …
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.
Corsi S, Stancampiano R, Carta M. Corsi S, et al. Prog Brain Res. 2021;261:287-302. doi: 10.1016/bs.pbr.2021.01.032. Epub 2021 Mar 3. Prog Brain Res. 2021. PMID: 33785132 Review.
Ample evidence suggests that the serotonergic system plays a major role in several aspects of Parkinson's disease. In this review, we focus on the interplay between dopamine and serotonin in the appearance of L-DOPA-induced dyskinesia (LID), the most troublesome sid …
Ample evidence suggests that the serotonergic system plays a major role in several aspects of Parkinson's disease. In this rev …
An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease.
Ayuso P, Jiménez-Jiménez FJ, Gómez-Tabales J, Alonso-Navarro H, García-Martín E, Agúndez JAG. Ayuso P, et al. Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(7):447-460. doi: 10.1080/17425255.2023.2249404. Epub 2023 Aug 24. Expert Opin Drug Metab Toxicol. 2023. PMID: 37599424 Review.
Thus, it has been suggested that pharmacogenomics may help to tailor and personalize drug therapy for Parkinson's disease. AREAS COVERED: This review describes and updates the clinical impact of genetic factors associated with the efficacy and adverse …
Thus, it has been suggested that pharmacogenomics may help to tailor and personalize drug therapy for Parkinson's disease …
Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
Politi C, Ciccacci C, Novelli G, Borgiani P. Politi C, et al. Neuromolecular Med. 2018 Mar;20(1):1-17. doi: 10.1007/s12017-017-8473-7. Epub 2018 Jan 5. Neuromolecular Med. 2018. PMID: 29305687 Review.
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by a progressive loss of dopamine neurons of the central nervous system. ...The identification of genomic biomarkers involved in drug response variability represents an important step in …
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by a progressive loss of dopamine neurons of th …
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Jing XZ, Yuan XZ, Luo X, Zhang SY, Wang XP. Jing XZ, et al. Curr Neuropharmacol. 2023;21(8):1806-1826. doi: 10.2174/1570159X20666220222150811. Curr Neuropharmacol. 2023. PMID: 35193486 Free PMC article. Review.
Nondopaminergic neurotransmitters such as adenosine, norepinephrine, serotonin, glutamate, and acetylcholine are all involved in Parkinson's disease (PD) and promote its symptoms. Therefore, nondopaminergic receptors are key targets for developing novel preparations …
Nondopaminergic neurotransmitters such as adenosine, norepinephrine, serotonin, glutamate, and acetylcholine are all involved in Parkinso …
Parkinson's disease in 1984: an update.
Lang AE, Blair RD. Lang AE, et al. Can Med Assoc J. 1984 Nov 1;131(9):1031-7. Can Med Assoc J. 1984. PMID: 6388779 Free PMC article. Review.
This update reviews several important topics in the field of Parkinson's disease, including etiologic studies, the types and mechanisms of drug complications and their treatment, when and how to begin treatment, the association of dementia with …
This update reviews several important topics in the field of Parkinson's disease, including etiologic studies, the type …
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D. Nyholm D. Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001. Clin Pharmacokinet. 2006. PMID: 16485914 Review.
Pharmacotherapy for Parkinson's disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. ...The long-duration of response to levodopa, which is evident in early Parkinson's disease, …
Pharmacotherapy for Parkinson's disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and do …
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
Cerri S, Blandini F. Cerri S, et al. Expert Opin Pharmacother. 2020 Dec;21(18):2279-2291. doi: 10.1080/14656566.2020.1805432. Epub 2020 Aug 17. Expert Opin Pharmacother. 2020. PMID: 32804544 Review.
INTRODUCTION: Long-term treatment of Parkinson's disease (PD) with levodopa is hampered by motor complications related to the inability of residual nigrostriatal neurons to convert levodopa to dopamine (DA) and use it appropriately. ...AREAS COV …
INTRODUCTION: Long-term treatment of Parkinson's disease (PD) with levodopa is hampered by motor complications r …
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.
Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Voon V, et al. Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229895 Review.
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control disorders also known as behavioural addictions. Levodopa-induc …
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated with motor and non-m …
53 results